Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen

Infection and Immunity

Volumn 75, Issue 11, 2007, Pages 5240-5247

  Brahmbhatt, Trupti N ^a,b   Darnell, Stephen C ^a   Carvalho, Humberto M ^a   Sanz, Patrick ^a   Kang, Tae J ^c   Bull, Robert L ^b   Rasmussen, Susan B ^a   Cross, Alan S ^c   O'Brien, Alison D ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTHRAX VACCINE; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 5; GLYCOPROTEIN; HISTIDINE; IMMUNOGLOBULIN G; PROTEIN BCLA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL IMMUNITY; BACTERIAL SPORE; BACTERIAL STRAIN; CONTROLLED STUDY; CROSS REACTION; DEATH; FEMALE; INOCULATION; LETHAL DOSE; MACROPHAGE; MOUSE; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RABBIT; SPORE GERMINATION; SURVIVAL; VACCINATION;

ANIMALS; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; COLLAGEN; CROSS REACTIONS; FEMALE; IMMUNIZATION, SECONDARY; MACROPHAGES, PERITONEAL; MEMBRANE GLYCOPROTEINS; MICE; SURVIVAL ANALYSIS; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 35649020232     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.00884-07     Document Type: Article

References (36)

1. Aronson, A. I., and P. Fitz-James. 1976. Structure and morphogenesis of the bacterial spore coat. Bacteriol. Rev. 40:360-402.
2. Bozue, J. A., N. Parthasarathy, L. R. Phillips, C. K. Cote, P. F. Fellows, I. Mendelson, A. Shafferman, and A. M. Friedlander. 2005. Construction of a rhamnose mutation in Bacillus anthracis affects adherence to macrophages but not virulence in guinea pigs. Microb. Pathog. 38:1-12.
3. Brachman, P. S., H. Gold, S. A. Plotkin, F. R. Fekety, M. Werrin, and N. R. Ingraham. 1962. Field evaluation of a human anthrax vaccine. Am. J. Public Health 52:632-645.
4. 3a. Brahmbhatt, T. N, B. K. Janes, E. S. Stibitz, S. C. Darnell, P. Sanz, S. B. Rasmussen, and A. D. O'Brien. 2007. Bacillus anthracis exosporium protein BclA affects spore germination, interaction with extracellular matrix proteins, and hydrophobicity. Infect. Immun. 75:5233-5239.
5. Brossier, F., M. Levy, and M. Mock. 2002. Anthrax spores make an essential contribution to vaccine efficacy. Infect. Immun. 70:661-664.
6. Cohen, S., I. Mendelson, Z. Altboum, D. Kobiler, E. Elhanany, T. Bino, M. Leitner, I. Inbar, H. Rosenberg, Y. Gozes, R. Barak, M. Fisher, C. Kronman, B. Velan, and A. Shafferman. 2000. Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax. Infect. Immun. 68:4549-4558.
7. Cote, C. K., C. A. Rossi, A. S. Kang, P. R. Morrow, J. S. Lee, and S. L. Welkos. 2005. The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions. Microb. Pathog. 38:209-225.
8. Cremer, M. A., E. F. Rosloniec, and A. H. Kang. 1998. The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. J. Mol. Med. 76:275-288.
9. Dixon, T. C., M. Meselson, J. Guillemin, and P. C. Hanna. 1999. Anthrax. N. Engl. J. Med. 341:815-826.
10. Doolan, D. L., D. A. Freilich, G. T. Brice, T. H. Burgess, M. P. Berzins, R. L. Bull, N. L. Graber, J. L. Dabbs, L. L. Shatney, D. L. Blazes, L. M. Bebris, M. F. Malone, J. F. Eisold, A. J. Mateczun, and G. J. Martin. 2007. The US Capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics. J. Infect. Dis. 195:174-184.
11. Elliott, J. L., J. Mogridge, and R. J. Collier. 2000. A quantitative study of the interactions of Bacillus anthracis edema factor and lethal factor with activated protective antigen. Biochemistry 39:6706-6713.
12. Enkhtuya, J., K. Kawamoto, Y. Kobayashi, I. Uchida, N. Rana, and S. Makino. 2006. Significant passive protective effect against anthrax by antibody to Bacillus anthracis inactivated spores that lack two virulence plasmids. Microbiology 152:3103-3110.
13. Fellows, P. F., M. K. Linscott, B. E. Ivins, M. L. Pitt, C. A. Rossi, P. H. Gibbs, and A. M. Friedlander. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247.
14. Gioud, M., A. Meghlaoui, O. Costa, and J. C. Monier. 1982. Antibodies to native type I and II collagens detected by an enzyme linked immunosorbent assay (ELISA) in rheumatoid arthritis and systemic lupus erythematosus. Coll. Relat. Res. 2:557-564.
15. Guidi-Rontani, C., M. Weber-Levy, E. Labruyere, and M. Mock. 1999. Germination of Bacillus anthracis spores within alveolar macrophages. Mol. Microbiol. 31:9-17.
16. Hahn, U. K., R. Boehm, and W. Beyer. 2006. DNA vaccination against anthrax in mice - combination of anti-spore and anti-toxin components. Vaccine 24:4569-4571.
17. Hanna, P. C., D. Acosta, and R. J. Collier. 1993. On the role of macrophages in anthrax. Proc. Natl. Acad. Sci. USA 90:10198-10201.
18. Ivins, B., P. Fellows, L. Pitt, J. Estep, J. Farchaus, A. Friedlander, and P. Gibbs. 1995. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 13:1779-1784.
19. Ivins, B. E., J. W. Ezzell, Jr., J. Jemski, K. W. Hedlund, J. D. Ristroph, and S. H. Leppla. 1986. Immunization studies with attenuated strains of Bacillus anthracis. Infect. Immun. 52:454-458.
20. Ivins, B. E., M. L. Pitt, P. F. Fellows, J. W. Farchaus, G. E. Benner, D. M. Waag, S. F. Little, G. W. Anderson, Jr., P. H. Gibbs, and A. M. Friedlander. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16:1141-1148.
21. Ivins, B. E., S. L. Welkos, S. F. Little, M. H. Crumrine, and G. O. Nelson. 1992. Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants. Infect. Immun. 60:662-668.
22. Kang, T. J., M. J. Fenton, M. A. Weiner, S. Hibbs, S. Basu, L. Baillie, and A. S. Cross. 2005. Murine macrophages kill the vegetative form of Bacillus anthracis. Infect. Immun. 73:7495-7501.
23. Leighton, T. J., and R. H. Doi. 1971. The stability of messenger ribonucleic acid during sporulation in Bacillus subtilis. J. Biol. Chem. 246:3189-3195.
24. Little, S. F., and G. B. Knudson. 1986. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect. Immun. 52:509-512.
25. Little, S. F., S. H. Leppla, and E. Cora. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 56:1807-1813.
26. Mock, M., and A. Fouet. 2001. Anthrax. Annu. Rev. Microbiol. 55:647-671.
27. Pittman, P. R., S. L. Norris, J. G. Barrera Oro, D. Bedwell, T. L. Cannon, and K. T. McKee, Jr. 2006. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 24:3654-3660.
28. Raines, K. W., T. J. Kang, S. Hibbs, G. L. Cao, J. Weaver, P. Tsai, L. Baillie, A. S. Cross, and G. M. Rosen. 2006. Importance of nitric oxide synthase in the control of infection by Bacillus anthracis. Infect. Immun. 74:2268-2276.
29. Steichen, C., P. Chen, J. F. Kearney, and C. L. Turnbough, Jr. 2003. Identification of the immunodominant protein and other proteins of the Bacillus anthracis exosporium. J. Bacteriol. 185:1903-1910.
30. Steichen, C. T., J. F. Kearney, and C. L. Turnbough, Jr. 2005. Characterization of the exosporium basal layer protein BxpB of Bacillus anthracis. J. Bacteriol. 187:5868-5876.
31. Sylvestre, P., E. Couture-Tosi, and M. Mock. 2002. A collagen-like surface glycoprotein is a structural component of the Bacillus anthracis exosporium. Mol. Microbiol. 45:169-178.
32. Turnbull, P. C. 2000. Current status of immunization against anthrax: old vaccines may be here to stay for a while. Curr. Opin. Infect. Dis. 13:113-120.
33. Turnbull, P. C. 1991. Anthrax vaccines: past, present and future. Vaccine 9:533-539.
34. Weaver, J., T. J. Kang, K. W. Raines, G. L. Cao, S. Hibbs, P. Tsai, L. Baillie, G. M. Rosen, and A. S. Cross. 2007. Protective role of Bacillus anthracis exosporium in macrophage-mediated killing by nitric oxide. Infect. Immun. 75:3894-3901.
35. Welkos, S. L., and A. M. Friedlander. 1988. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb. Pathog. 5:127-139.
36. Zaucha, G. M., L. M. Pitt, J. Estep, B. E. Ivins, and A. M. Friedlander. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch. Pathol. Lab. Med. 122:982-992.